P/B
33,9
Kodiak Sciences
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
$2.1B
Market Cap • 9/11/2026
2009
(17 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,1
EPS
—
Market Cap
Market Cap
2,1B
EV
2B
EV/Revenue
0
EV/EBITDA
-9,1
EV/EBIT
-8,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-8,8%
Total Yield
-8,8%
Payout
0%
Retained Earnings
-1,7B
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
5,5%
Capex/OCF
-0,9%
SBC/OCF
—
% PPE
43,1%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
5,3%
CAGR Net Income 5Y
5,1%
CAGR EPS 5Y
1,8%
CAGR OCF 5Y
5,2%
Leverage
N.D./EBITDA
0,3
Debt/Equity
0%
Current Ratio
2,5
Quick Ratio
2,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!